Enanta Pharmaceuticals, Inc. (ENTA)
10.71
-0.44
(-3.95%)
USD |
NASDAQ |
Oct 30, 16:00
10.76
+0.06
(+0.51%)
After-Hours: 20:00
Enanta Pharmaceuticals Enterprise Value : 304.41M for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | 304.41M |
| October 29, 2026 | 317.22M |
| October 28, 2026 | 328.87M |
| October 27, 2026 | 347.22M |
| October 26, 2026 | 341.97M |
| October 23, 2026 | 331.49M |
| October 22, 2026 | 330.91M |
| October 21, 2026 | 321.88M |
| October 20, 2026 | 332.36M |
| October 19, 2026 | 324.79M |
| October 16, 2026 | 315.77M |
| October 15, 2026 | 326.54M |
| October 14, 2026 | 318.10M |
| October 13, 2026 | 328.00M |
| October 12, 2026 | 350.71M |
| October 09, 2026 | 356.53M |
| October 08, 2026 | 344.89M |
| October 07, 2026 | 352.75M |
| October 06, 2026 | 346.92M |
| October 05, 2026 | 359.45M |
| October 02, 2026 | 369.93M |
| October 01, 2026 | 366.43M |
| September 30, 2026 | 376.34M |
| September 29, 2026 | 360.61M |
| September 28, 2026 | 359.88M |
| Date | Value |
|---|---|
| September 25, 2026 | 338.48M |
| September 24, 2026 | 341.97M |
| September 23, 2026 | 340.52M |
| September 22, 2026 | 354.20M |
| September 21, 2026 | 345.18M |
| September 18, 2026 | 347.80M |
| September 17, 2026 | 357.12M |
| September 16, 2026 | 362.36M |
| September 15, 2026 | 350.42M |
| September 14, 2026 | 374.59M |
| September 11, 2026 | 369.93M |
| September 10, 2026 | 362.36M |
| September 09, 2026 | 378.08M |
| September 08, 2026 | 385.65M |
| September 04, 2026 | 402.54M |
| September 03, 2026 | 400.80M |
| September 02, 2026 | 402.83M |
| September 01, 2026 | 385.95M |
| August 31, 2026 | 380.70M |
| August 28, 2026 | 388.57M |
| August 27, 2026 | 394.39M |
| August 26, 2026 | 404.58M |
| August 25, 2026 | 402.54M |
| August 24, 2026 | 403.13M |
| August 21, 2026 | 384.78M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Perspective Therapeutics, Inc. | -101.71M |
| Vertex Pharmaceuticals, Inc. | 135.71B |
| Coherus Oncology, Inc. | 77.10M |
| BridgeBio Pharma, Inc. | 17.52B |
| RenovoRx, Inc. | 50.92M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.50M |
| Revenue (Quarterly) | 14.36M |
| Total Expenses (Quarterly) | 33.86M |
| EPS Diluted (Quarterly) | -0.6704 |
| Gross Profit Margin (Quarterly) | 91.75% |
| Profit Margin (Quarterly) | -135.8% |
| Earnings Yield | -22.51% |
| Normalized Earnings Yield | -22.51 |